Axsome Therapeutics Announced Seven Presentations On AXS-12 And Solriamfetol At Sleep Europe 2024
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics will present data on AXS-12 and solriamfetol at Sleep Europe 2024, including Phase 3 trial results for AXS-12 in narcolepsy and findings on solriamfetol's cognitive benefits for EDS patients.
September 24, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics is set to present significant data on AXS-12 and solriamfetol at Sleep Europe 2024, which could positively impact its stock price due to potential advancements in narcolepsy treatment.
The announcement of presentations at a major conference like Sleep Europe 2024 suggests that Axsome Therapeutics is making progress in its clinical trials, particularly with AXS-12 in narcolepsy. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90